利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.018 秒)

    Biomarker of Renal Impairment
    1.
    发明申请
    Biomarker of Renal Impairment 审中-公开
    肾损伤生物标志物

    公开(公告)号：US20140221507A1

    公开(公告)日：2014-08-07

    申请号：US14131212

    申请日：2012-07-02

    申请人： Jochen Schwenk ,  Peter Nilsson ,  Mathias Uhlén

    发明人： Jochen Schwenk ,  Peter Nilsson ,  Mathias Uhlén

    IPC分类号： G01N33/68

    CPC分类号： G01N33/6893 ,  G01N33/493 ,  G01N2800/347

    摘要： There is provided a method of determining whether a subject belongs to a first or a second group of subjects, wherein the risk of having or developing of a renal impairment is higher in the first group than in the second group, comprising the steps of: a) measuring an amount of fibulin 1 in a sample from the subject to obtain a sample value; b) comparing the sample value to a reference value; and if the sample value is higher than the reference value, c1) concluding that the subject belongs to the first group; and if the sample value is lower than the reference value, c2) concluding that the subject belongs to the second group, wherein the sample is an optionally modified sample derived from urine or blood, such as an optionally diluted serum or plasma sample. Associated means are also provided.

    摘要翻译： 提供了确定受试者是否属于第一组或第二组受试者的方法，其中在第一组中具有或发展肾损伤的风险高于第二组，其包括以下步骤：a ）测量来自受试者的样品中的纤维蛋白1的量以获得样品值; b）将样本值与参考值进行比较; 并且如果样本值高于参考值，则c1）认定该受试者属于第一组; 并且如果样品值低于参考值，则c2）断定受试者属于第二组，其中样品是衍生自尿液或血液的任选修饰的样品，例如任选稀释的血清或血浆样品。 还提供了相关的手段。

    Activating a reversibly inactivated immobilized enzyme by release from an immobilizing moiety
    3.
    发明授权
    Activating a reversibly inactivated immobilized enzyme by release from an immobilizing moiety 失效
    通过从固定部分释放来活化可逆灭活的固定化酶

    公开(公告)号：US06610479B1

    公开(公告)日：2003-08-26

    申请号：US08952570

    申请日：1998-02-13

    申请人： Joakim Lundeberg ,  Mathias Uhlén

    发明人： Joakim Lundeberg ,  Mathias Uhlén

    IPC分类号： C12Q168

    CPC分类号： C12Q1/6848 ,  C07K14/315 ,  C07K14/70535 ,  C07K2319/00 ,  C12N9/1252 ,  C12Q1/686 ,  Y10S435/81 ,  C12Q2549/107 ,  C12Q2527/127

    摘要： Enzymes or catalytic fragments thereof reversibly inactivated by attachment to an immobilizing moiety which may comprise a magnetic particle are activated by release from the immobilizing moiety. The enzyme or fragment may be in the form of a fusion protein that is attached to the immobilizing moiety via a pair of affinity binding partners such that the enzyme or fragment is reversibly inactivated, and release of the fusion protein from the immobilizing moiety activates the enzyme or fragment. Enzymes include DNA polymerases, DNA ligases, Reverse transcriptases and RNA polymerases. The enzyme or fragment may be thermostable, and the fusion protein can be bound to the immobilizing moiety via a heat-labile linkage. Activation of the reversibly inactivated immobilized enzyme or fragment has particular utility in PCR and analogous nucleic acid amplification techniques. A sample containing a nucleic acid is contacted with the immobilized fusion protein, and release of the fusion protein activates the enzyme or fragment to start a first cycle of an amplification reaction. Amplification reactions that may be carried out include Ligase chain reaction (LCR), Self-sustained Sequence Replication (3SR), Reverse transcriptase PCR (RT-PCR), Q-beta replicase amplification reaction and nucleic acid sequence-based amplification (NASBA). Kits for the amplifications may be prepared containing an appropriate reversibly immobilized enzyme in the form of a fusion protein, and primers and/or probe for performing the amplification.

    摘要翻译： 通过与固定部分连接可逆地失活的酶或其催化片段可以由固定化部分释放而被活化。 酶或片段可以是融合蛋白的形式，其通过一对亲和结合配偶体与固定化部分连接，使得酶或片段可逆地失活，并且融合蛋白从固定化部分的释放激活酶 或片段。 酶包括DNA聚合酶，DNA连接酶，逆转录酶和RNA聚合酶。 酶或片段可以是热稳定的，并且融合蛋白可以通过热不稳定连接键与固定部分结合。 可逆灭活的固定化酶或片段的活化在PCR和类似的核酸扩增技术中具有特别的用途。 将含有核酸的样品与固定化的融合蛋白接触，并且融合蛋白的释放激活酶或片段以开始扩增反应的第一循环。 可能进行的扩增反应包括连接酶链反应（LCR），自持序列复制（3SR），逆转录酶PCR（RT-PCR），Q-β复制酶扩增反应和基于核酸序列的扩增（NASBA）。 可以制备用于扩增的试剂盒，其含有融合蛋白形式的合适的可逆固定的酶，以及用于进行扩增的引物和/或探针。

    Means and Method for Ovarian Cancer Prognosis
    5.
    发明申请
    Means and Method for Ovarian Cancer Prognosis 审中-公开
    卵巢癌预后的手段和方法

    公开(公告)号：US20120058202A1

    公开(公告)日：2012-03-08

    申请号：US13201740

    申请日：2010-02-16

    申请人： Mathias Uhlén ,  Fredrik Pontén ,  Karin Jirström ,  Donal J. Brennan

    发明人： Mathias Uhlén ,  Fredrik Pontén ,  Karin Jirström ,  Donal J. Brennan

    IPC分类号： A61K31/555 ,  C12Q1/68 ,  C40B30/04 ,  C07K16/18 ,  C07K14/47 ,  C07K7/06 ,  C07K4/12 ,  G01N33/574 ,  A61P35/00

    CPC分类号： G01N33/689 ,  C07K14/4748 ,  G01N33/5743

    摘要： There is provided a method for determining whether a mammalian subject having an ovarian cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group, comprising the steps of: a) evaluating an amount of RBM3 protein in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; b) comparing said sample value with a predetermined refer-ence value; and if said sample value is higher than said ref-erence value, c1) concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, c2) concluding that the sub-ject belongs to the second group. Related peptides, affinity ligands, uses and further methods are also provided.

    摘要翻译： 提供了一种用于确定具有卵巢癌的哺乳动物受试者是否属于第一组或第二组的方法，其中第一组受试者的预后优于第二组受试者的预后，包括以下步骤： a）评估早期从受试者获得的样品的至少一部分中的RBM3蛋白的量，并确定对应于评估量的样品值; b）将所述样本值与预定参考值进行比较; 并且如果所述样本值高于所述参考值，则c1）得出结论，所述受试者属于第一组; 并且如果所述样本值小于或等于所述参考值，则c2）推断子项目属于第二组。 还提供了相关肽，亲和配体，用途和其它方法。

    Receptor structures
    6.
    发明授权
    Receptor structures 有权
    受体结构

    公开(公告)号：US06602977B1

    公开(公告)日：2003-08-05

    申请号：US09549441

    申请日：2000-04-14

    申请人： Charlotta Ljungqvist ,  Karin Nord ,  Per-Åke Nygren ,  Mathias Uhlén

    发明人： Charlotta Ljungqvist ,  Karin Nord ,  Per-Åke Nygren ,  Mathias Uhlén

    IPC分类号： A61K3800

    CPC分类号： C07K14/31 ,  C12N15/1034

    摘要： The present invention relates to modified polypeptide derivatives of the B domain or Z domain of staphylococcal protein A (SPA). The derivatives contain amino acid substitutions that result in the ability of the B domain or Z domain to interact with at least one domain of a human Factor VIII protein, without substantially disrupting the structure and stability of the B domain or Z domain.

    摘要翻译： 本发明涉及葡萄球菌蛋白A（SPA）的B结构域或Z结构域的修饰多肽衍生物。 衍生物含有导致B结构域或Z结构域与人因子VIII蛋白的至少一个结构域相互作用的能力的氨基酸取代，而基本上不破坏B结构域或Z结构域的结构和稳定性。

    RBM3 in colorectal cancer prognostics
    7.
    发明授权
    RBM3 in colorectal cancer prognostics 有权
    RBM3在结肠直肠癌预后中的作用

    公开(公告)号：US08728739B2

    公开(公告)日：2014-05-20

    申请号：US13210816

    申请日：2011-08-16

    申请人： Mathias Uhlén ,  Fredrik Pontén ,  Karin Jirström

    发明人： Mathias Uhlén ,  Fredrik Pontén ,  Karin Jirström

    IPC分类号： C12Q1/68 ,  G01N33/53

    CPC分类号： C07K16/18 ,  A61K31/7068 ,  A61K39/39533 ,  A61K45/06 ,  C07K14/4748 ,  C07K16/3038 ,  C07K2317/34 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N33/57419 ,  A61K2300/00

    摘要： The present invention provides means, such as a method, for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA molecule in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; andif said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.

    摘要翻译： 本发明提供了用于确定具有结肠直肠癌的哺乳动物受试者是否属于第一组或第二组的方法，例如方法，其中第一组受试者的预后优于第二组受试者的预后 。 该方法包括以下步骤：评估早期从受试者获得的样品的至少部分中的RBM3蛋白或RBM3 mRNA分子的量，并确定对应于评估量的样品值; 将所述样本值与预定参考值进行比较; 并且如果所述样本值高于所述参考值，则认定所述对象属于所述第一组; 并且如果所述样本值低于或等于所述参考值，则认定所述对象属于所述第二组。

    IMMUNODETECTABILITY
    9.
    发明申请
    IMMUNODETECTABILITY 审中-公开
    免疫性

    公开(公告)号：US20120178108A1

    公开(公告)日：2012-07-12

    申请号：US13379798

    申请日：2009-06-26

    申请人： Mathias Uhlén ,  Jochen Schwenk

    发明人： Mathias Uhlén ,  Jochen Schwenk

    IPC分类号： G01N21/64 ,  G01N33/82 ,  G01N33/53

    CPC分类号： G01N33/5306 ,  G01N33/5375

    摘要： In the present disclosure, there is provided a method for improving the immunodetectability of at least one protein in an optionally diluted sample of blood, serum or plasma, comprising a step of heating the sample to a temperature of 64-85° C. prior to a contact between the sample and at least one affinity ligand for detection and/or quantification of the at least one protein.

    摘要翻译： 在本公开内容中，提供了一种用于提高任选稀释的血液，血清或血浆样品中至少一种蛋白质的免疫检测性的方法，包括将样品加热至温度为64-85℃， 所述样品和至少一种亲和配体之间的接触用于所述至少一种蛋白质的检测和/或定量。